Key statistics
On Friday, Organovo Holdings Inc (ONVO:NAQ) closed at 0.4964, 5.53% above its 52-week low of 0.4704, set on Sep 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.51 |
---|---|
High | 0.51 |
Low | 0.4704 |
Bid | 0.4268 |
Offer | 0.526 |
Previous close | 0.5070 |
Average volume | 57.65k |
---|---|
Shares outstanding | 15.36m |
Free float | 15.05m |
P/E (TTM) | -- |
Market cap | 7.63m USD |
EPS (TTM) | -1.39 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
- Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
- Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
- Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
- Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
- Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
- Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
- Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
- CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
More ▼